TTrialPathMatch Me to Trials
← Back to trials
RecruitingPancreatic Cancer

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to determine the optimal dose of AGEN2373 that is safe when given in combination with balstilimab and Pancreatic GVAX Whole Cell Vaccine and evaluate the safety and clinical activity of balstilimab and AGEN2373 in combination with GVAX (Arm 1) or mKRASvax (Arm 2) in surgically resectable pancreatic adenocarcinoma.

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

You may qualify if…

  • ✓ Have a newly diagnosed, biopsy-proven adenocarcinoma of the pancreas.
  • ✓ Tumor must be deemed resectable by the study team
  • ✓ Patient's acceptance to have a tumor biopsy.
  • ✓ Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
  • ✓ Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures.
  • ✓ Women of childbearing potential (WOCBP) must have a negative serum pregnancy test.
  • ✓ For both Women and Men, must use acceptable form of birth control while on study.

You may not qualify if…

  • ✕ Received any anti-pancreatic cancer therapy (symptomatic therapies are allowed), or any prior anti-cancer immunotherapy.
  • ✕ Diagnosed with another cancer whose natural history or treatment could interfere with safety or efficacy assessments on this study.
  • ✕ Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
  • ✕ Active autoimmune disease.
  • ✕ Systemic steroid therapy (\> 10mg daily prednisone equivalent) or immunosuppressive therapy within 14 days of first dose of study drug administration.
  • ✕ Active infection requiring systemic therapy.
  • ✕ Known history of human immunodeficiency virus (HIV).
  • ✕ Active or chronic hepatitis B or hepatitis C.

Where it's recruiting

Maryland

Baltimore

Source: ClinicalTrials.gov · NCT06782932 · last updated 2025-12-03

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 · TrialPath